By Denny Jacob
Humacyte shares surged 38% in premarket trading a day after disclosing the Food and Drug Administration granted full approval of Symvess for adults.
Shares were trading around $4.81. The stock is up 22% on the year.
The biotechnology company said the approval applies to use of the treatment as a vascular conduit for extremity arterial injury when blood flow needs to urgently be restored to avoid imminent limb loss, and when a graft of a vein used to repair blood vessels isn't feasible.
Symvess was used to repair many types of traumatic injuries including car accidents, gunshot wounds, blast wounds and industrial accidents, said Humacyte.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 20, 2024 06:56 ET (11:56 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。